Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2026 Sep 28;17:1987050. doi: 10.3389/fimmu.2026.1987050

Correction: Efficacy and safety of camrelizumab plus apatinib for solid tumors: a meta-analysis

Ping Yu 1,†, Xiaoyu Song 1,2,†, Yue Li 1, Xuanlong Chen 1,2, Yuan Zhou 1,3,*, Fei Jiang 3,*
PMCID: PMC13655547  PMID: 42865897

In the published article, an incorrect Funding statement was provided. The statement read: “The author(s) declare that no financial support was received for the research and/or publication of this article.”

The Funding statement has been corrected to read: “The author(s) declare that financial support was received for the research and/or publication of this article. This research was funded by a special grant for stem cell research from Taihe Hospital in Shiyan (GXB23015) and Natural Science Foundation of Hubei Province, China (2024AFB848).”

The original version of this article has been updated.

Footnotes

Approved by: https://loop.frontiersin.org/people/111428,

Frontiers Media SA, Lausanne, Switzerland

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES